Form 4: Arcutis CEO Sells Shares Under Pre-Arranged Plan

Arcutis Biotherapeutics CEO Todd Watanabe sold 40,000 shares of common stock for approximately $25.03 per share under a Rule 10b5-1 trading plan.

Summary

• Todd Watanabe, President and Chief Executive Officer, and a Director of Arcutis Biotherapeutics, Inc. (ARQT), reported a sale of common stock.
• The transaction involved the disposition of 40,000 shares of Arcutis Biotherapeutics common stock.
• The shares were sold at a weighted average price of $25.0258 per share.
• The total value of the shares sold is approximately $1,001,032.
• The sale was executed on October 28, 2025.
• This transaction was conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Watanabe on June 3, 2025, with a plan end date of September 30, 2026.
• Following this transaction, Mr. Watanabe directly beneficially owns 806,440 shares of common stock.
• He also indirectly beneficially owns 25,410 shares through The John Franklin Watanabe Trust, 25,410 shares through The Anderson Prest Watanabe Irrevocable Trust, 57,358 shares through Watanabe Ventures, LLC, and 124,956 shares through The Watanabe 2016 Irrevocable Trust.

Sentiment

Score: 5

Explanation: A planned insider stock sale under a Rule 10b5-1 plan is generally considered a neutral event, as it is pre-scheduled and not necessarily indicative of management's immediate view on the company's prospects.

Future Outlook

N/A

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide information relevant to broader industry trends or competitive analysis.

Related Party Transactions

• The filing details indirect beneficial ownership through trusts (The John Franklin Watanabe Trust, The Anderson Prest Watanabe Irrevocable Trust, The Watanabe 2016 Irrevocable Trust) and an LLC (Watanabe Ventures, LLC) where the reporting person has a relationship (e.g., trustee, COO). However, the reported transaction is a direct sale by the reporting person, not a transaction with these related parties.

Stakeholder Impact

• The sale of 40,000 shares by the CEO is a routine insider transaction under a pre-arranged plan and is unlikely to have a significant direct impact on shareholders, employees, customers, suppliers, or creditors. It represents a small fraction of the company's total outstanding shares and the CEO's overall holdings.

Next Steps

• The Rule 10b5-1 plan has an end date of September 30, 2026, implying potential future transactions under the plan, but no specific future actions are detailed.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Todd Watanabe, insider trading, Form 4, stock sale, 10b5-1 plan, CEO, Director, common stock, biotherapeutics